Brand of the Year: Januvia - Pharmaceutical Executive

ADVERTISEMENT

Brand of the Year: Januvia


Pharmaceutical Executive


Origin story

Drug discovery, development, and commercial approval depend on both the strength of a product candidate and a healthy dose of serendipity.

Perhaps the most compelling support for Merck's decision to buck the Big Pharma trend of devoting a majority of R&D resources to in-licensing later-stage products to fill its pipelines, as opposed to spending those resources on internal development, is the story of Januvia. Interestingly, Merck's DPP-4 project began with an in-licensed drug candidate, from a privately-held German biotech called Probiodrug.

In a Probiodrug press release from 2000, Bennett Shapiro, then Merck's EVP, worldwide licensing and external research, said the agreement marked "an aggressive new focus on external collaborations…bringing the best science to Merck and broadening our future new product base." The last part of that statement was prescient, even though the Probiodrug candidate was ultimately terminated. But "it was really the things we'd learned from [the Probiodrug] molecule that resulted in the identification of sitagliptin, which is the molecule that was discovered internally," says Thornberry.




Merck first became interested in the DPP-4 mechanism based on research conducted in the 1990s, which validated the glucagon-like peptide 1 (GLP-1) target, the substrate for DPP-4, as a target for diabetes. "The second key piece of data was evidence showing that DPP-4 was the enzyme involved in the regulation of GLP-1," says Thornberry.

After reviewing preclinical models of diabetes and DPP-4 inhibition published by Probiodrug and Novartis, Merck began its DPP-4 project in earnest in the summer of 1999. Three years later, in July of 2002, sitagliptin entered into a focused clinical development program. Thanks to the "full support of the organization," Januvia developers "adopted a somewhat streamlined clinical development program in that, as others had demonstrated proof of concept, we were able to use a direct to [Phase] IIb strategy," says Thornberry. "From the initial Phase I studies, we were able to go directly to IIb, and that was one of the mechanisms we used to move the program more rapidly through development." That and the fact that "there were really no safety issues at all…either in preclinical studies or in the course of our clinical program, that caused us to slow down."

Merck's sitagliptin development team also realized from the start that "it was going to be critically important to demonstrate efficacy in combination with metformin," a member of the biguanide class of drugs, and an important first-line therapy, along with the sulfonylurea drug class, for Type 2 diabetes around the globe. As a result, sitagliptin was developed as a monotherapy and as a fixed-dose combination with metformin.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here